Victor Moreno, Director of Clinical Research at START Madrid FJD, shared on LinkedIn:
“How much evidence should be required before taking a new drug into a phase 3 trial?
AstraZeneca has discontinued the phase 3 eVOLVE-Lung02 trial after an independent monitoring committee concluded that volrustomig plus chemotherapy was unlikely to improve PFS or OS over pembrolizumab plus chemotherapy in the primary population of patients with metastatic NSCLC and PD-L1-negative tumors.
Volrustomig is a bispecific antibody designed to deliver coordinated PD-1 and CTLA-4 blockade on the same T cell—a compelling biological concept. Yet compelling biology does not necessarily translate into superiority against an effective standard of care.
The trial enrolled 895 patients across 25 countries. No new safety signals were identified, and phase 3 studies of volrustomig in other tumor types are continuing.
The announcement cannot tell us whether the result reflects the target, the molecule, patient selection, treatment context, or the difficulty of outperforming a strong active comparator. Full data will be needed.
But the development question remains important: before moving into phase 3, should we require randomized evidence of added clinical activity, stronger pharmacodynamic confirmation, or a biomarker-defined population – rather than mechanistic rationale and encouraging single-arm results alone?
Negative phase 3 trials are not simply failures. They should help recalibrate the evidence thresholds used for early-phase go/no-go decisions.”
